Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Senesco Technologies Inc. (ELOX : NSDQ)
 
 • Company Description   
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Number of Employees: 25

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.35 Daily Weekly Monthly
20 Day Moving Average: 284,791 shares
Shares Outstanding: 86.65 (millions)
Market Capitalization: $30.25 (millions)
Beta: 2.47
52 Week High: $2.53
52 Week Low: $0.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.91% 1.47%
12 Week -18.81% -10.74%
Year To Date -50.57% -39.60%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
480 ARSENAL WAY
-
WATERTOWN,MA 02472
USA
ph: 781-577-5300
fax: 908-864-4440
ir@bgstaffing.com http://www.eloxxpharma.com
 
 • General Corporate Information   
Officers
Sumit Aggarwal - President; Chief Executive Officer and Director
Tomer Kariv - Chairman
Daniel E. Geffken - Chief Financial Officer
Ran Nussbaum - Director
Rajesh Parekh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29014R103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 86.65
Most Recent Split Date: 12.00 (0.05:1)
Beta: 2.47
Market Capitalization: $30.25 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.48 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.59
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 40.91%
vs. Previous Quarter: 7.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -174.48
12/31/21 - -178.41
09/30/21 - -175.91
ROA
03/31/22 - -91.79
12/31/21 - -97.10
09/30/21 - -93.58
Current Ratio
03/31/22 - 2.20
12/31/21 - 4.37
09/30/21 - 5.63
Quick Ratio
03/31/22 - 2.20
12/31/21 - 4.37
09/30/21 - 5.63
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.13
12/31/21 - 0.26
09/30/21 - 0.38
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 1.04
12/31/21 - 0.54
09/30/21 - 0.36
Debt-to-Capital
03/31/22 - 50.91
12/31/21 - 34.89
09/30/21 - 26.52
 

Powered by Zacks Investment Research ©